SLE Survival Rates Improving, But Lupus Nephritis Risk High Among Non-White Patients
Researchers investigated the patient factors that affect risk for mortality and lupus nephritis among patients with SLE.
All articles by Rheumatology Advisor Contributing Writer
Ultrasound-Defined Tenosynovitis May Predict Development of Persistent Arthritis
Researchers investigated the use of ultrasound-defined tenosynovitis in predicting the persistence of inflammatory arthritis.
Ixekizumab Demonstrates Tolerability and Safety Profile Consistent With Known Safety Profile in PsA
A team of researchers performed an integrated safety analysis from 4 clinical trials among patients with psoriatic arthritis to assess the safety profile of ixekizumab.
High Sensitivity, Low Specificity of EULAR/ACR 2019 Criteria for Childhood-Onset SLE
Researchers compared the sensitivity and specificity of the EULAR/ACR 2019 classification criteria with prior classification criteria among patients with childhood-onset systemic lupus erythematosus.
Clinical Characteristics of Patients With Rheumatic Disease With Breakthrough COVID-19 Assessed
Using data from the COVID-19 Global Rheumatology Alliance, researchers studied the clinical characteristics of patients with rheumatic disease who developed SARS-CoV-2 breakthrough infections.
![There are no uniform guidelines regarding DMARD tapering. EULAR guidelines suggest RA pharmacotherapy should be de-escalated in the following order: glucocorticoids, biologic DMARDs, and, finally, conventional DMARDs, with each treatment stopping completely before de-escalation of the next agent in the sequence.[4] Numerous DMARD dose-tapering protocols have been studied, including immediate discontinuation of treatment. When the goal is to withdraw treatment, the ACR recommends an initial dose-tapering phase to enable better monitoring of patient response and candidacy for discontinuation.[5] The ACR also strongly encourages patient involvement in decisions regarding their individual DMARD tapering protocol.](https://www.rheumatologyadvisor.com/wp-content/uploads/sites/18/2019/01/syringedrugsts53728911801_1026507-544x306.jpg)
Comparing the Efficacy, Safety of Systemic Therapies in the Treatment of PsA Manifestations
Authors of a systematic review compared the efficacy and safety of systemic therapies in the treatment of manifestations of active psoriatic arthritis.
SLE Diagnosed During Hospitalization Associated With Higher Disease Activity, Damage, and Death
Researchers aimed to study the outcomes of patients with systemic lupus erythematosus diagnosed during hospitalization.
Reduced Humoral Response to COVID-19 Vaccine Among Patients With PsA Receiving Immunomodulatory Therapy
The aim of the study was to determine the effect of psoriatic arthritis therapy on COVID-19 vaccination response.
What Is the Effect of Changing Medication Patterns on Remission Rates in JIA?
Significantly more patients with JIA stopped taking their medications over a period of 18 vs 8 years after disease onset.
Remission and Low Disease Activity State Improve Health-Related Quality of Life in SLE
Researchers investigated the effect of remission and lupus low disease activity state on health-related quality of life in patients with systemic lupus erythematosus.
- Loading...
Loading...
Next post in Systemic Lupus Erythematosus
Loading... 
Loading...